Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies

Next Previous
Search
Trial Profile

A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CRX 100 (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Colorectal cancer; Gastric cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Osteosarcoma; Ovarian cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors BioEclipse Therapeutics

    • Most Recent Events

    • 29 Jan 2024 Protocol amended to add combination cohorts with Fludarabine, cyclophosphamide and Pembrolizumab. Patient number changed. Inclusion criteria amended to include NSCLC and malignant melanoma.
    • 29 Jan 2024 Planned number of patients changed from 24 to 60.
    • 29 Jan 2024 Planned End Date changed from 1 Mar 2025 to 1 Oct 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top